<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="17803"><DrugName>CGS-27023A analogs (respiratory disease), Novartis</DrugName><DrugSynonyms><Name><Value>CGS-27023A analogs (respiratory disease), Novartis</Value></Name><Name><Value>elastase inhibitors (respiratory disease), Novartis</Value></Name></DrugSynonyms><CompanyOriginator id="23137">Novartis AG</CompanyOriginator><CompaniesSecondary><Company id="23137">Novartis AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="111" type="ciIndication"><TargetEntity id="J43" type="ICD10"/><TargetEntity id="492" type="ICD9"/><TargetEntity id="10014561" type="MEDDRA"/><TargetEntity id="D004646" type="MeSH"/><TargetEntity id="-1329111132" type="omicsDisease"/><TargetEntity id="282" type="siCondition"/></SourceEntity><SourceEntity id="711" type="ciIndication"><TargetEntity id="J98.9" type="ICD10"/><TargetEntity id="10038683" type="MEDDRA"/><TargetEntity id="D012140" type="MeSH"/><TargetEntity id="-2143937119" type="omicsDisease"/><TargetEntity id="269" type="siCondition"/></SourceEntity><SourceEntity id="2460" type="Action"><TargetEntity id="454" type="Mechanism">MMP-1 (Interstitial Collagenase) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2400" type="Action"><TargetEntity id="457" type="Mechanism">MMP-3 (Stromelysin 1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="154" type="Action"><TargetEntity id="420" type="Mechanism">Elastase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01319" type="ciTarget"><TargetEntity id="187841556743123" type="siTarget">Interstitial collagenase</TargetEntity><TargetEntity id="498" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01321" type="ciTarget"><TargetEntity id="176569477943143" type="siTarget">Stromelysin-1</TargetEntity><TargetEntity id="2267" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="111">Emphysema</Indication><Indication id="711">Respiratory disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="154">Elastase inhibitor</Action><Action id="2460">Metalloprotease-1 inhibitor</Action><Action id="2400">Metalloprotease-3 inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2007-08-15T15:29:00.000Z</LastModificationDate><ChangeDateLast>2007-08-15T15:29:00.000Z</ChangeDateLast><AddedDate>1998-05-06T10:59:40.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt; was investigating a series of sulfonamide-based analogs of &lt;ulink linkType="Drug" linkID="8650"&gt;CGS-27023A&lt;/ulink&gt; which showed inhibitory activity aginst metalloprotease-1 and 3 for the potential treatment of chronic respiratory diseases such as emphysema [&lt;ulink linkType="reference" linkID="286130"&gt;286130&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;Two of the compounds isolated by 1998 had IC50 values of 4.9 and 4.8 nM against Escherichia coli-expressed mouse macrophage elastase [&lt;ulink linkType="reference" linkID="286130"&gt;286130&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Compounds with improved activity of MMP-1 and MMP-3 inhibitors, reported in March 1999, were obtained by increasing the size of the sulfonamide ring to a 6- or 7-membered ring. The activity was optimized by modification of the 6-membered ring. Solubility was improved from 0.005 mg/ml to 0.45 mg/ml by the introduction of polar substituents, although this reduced activity [&lt;ulink linkType="reference" linkID="319228"&gt;319228&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="711">Respiratory disease</Indication><StatusDate>2007-08-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="111">Emphysema</Indication><StatusDate>2007-08-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="711">Respiratory disease</Indication><StatusDate>1998-05-06T00:00:00.000Z</StatusDate><Source id="286130" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="111">Emphysema</Indication><StatusDate>1998-05-06T00:00:00.000Z</StatusDate><Source id="286130" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00652"><Name>Elastase</Name><SwissprotNumbers/></Target><Target id="PTGT-01319"><Name>Metalloprotease-1</Name><SwissprotNumbers><Swissprot>P03956</Swissprot><Swissprot>P13943</Swissprot><Swissprot>P21692</Swissprot><Swissprot>P28053</Swissprot><Swissprot>P81563</Swissprot><Swissprot>Q11133</Swissprot><Swissprot>Q9EPL5</Swissprot><Swissprot>Q9EPL6</Swissprot><Swissprot>Q9XSZ5</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01321"><Name>Metalloprotease-3</Name><SwissprotNumbers><Swissprot>P03957</Swissprot><Swissprot>P08254</Swissprot><Swissprot>P28862</Swissprot><Swissprot>P28863</Swissprot><Swissprot>Q28397</Swissprot><Swissprot>Q6Y4Q5</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>